课题基金 / 基金详情

A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY

A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY
每日给予 VEGF 反义寡核苷酸 (VEGF-AS) 的 I 期研究
批准号：
7982116
负责人：
DAVID IAN QUINN
金额：
$4.06万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
项目状态：
已结题
起止时间：
2008-12-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7982116
关键词：
Antisense OligonucleotidesClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDoseFundingGrantInstitutionMalignant NeoplasmsPatientsPhase I Clinical TrialsRefractoryRelapseResearchResearch PersonnelResourcesSourceSubcutaneous InjectionsUnited States National Institutes of HealthVascular Endothelial Growth Factors

项目摘要

项目成果

DAVID IAN QUINN的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I study of VEGF-Antisense Oligonucleotide (VEGF-AS) given as a daily fixed dose subcutaneous injection in the treatment of patients with relapsed or refractory malignancies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR
Clinical Investigations Support Office
海外基金